Management of Patients with Inflammatory Diseases during the COVID-19 Pandemic

Patients with inflammatory diseases who receive moderate or high-risk anti-inflammatory therapies might be considered as an increased risk group for severe COVID-19 and appropriate measures should be taken in order to protect them. . Initiation of immuno-suppressive/modulatory therapies should be do...

Descripción completa

Detalles Bibliográficos
Autores principales: Apostolou, Theofanis, Koutroubakis, Ioannis E., Manolakopoulos, Spilios, Mantzaris, Gerasimos, Rigopoulos, Dimitrios, Triantafyllou, Konstantinos, Vassilopoulos, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Mediterranean Journal of Rheumatology (MJR) 2020
Materias:
Joint Position Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656124/
https://www.ncbi.nlm.nih.gov/pubmed/33196008
http://dx.doi.org/10.31138/mjr.31.3.295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656124/
https://www.ncbi.nlm.nih.gov/pubmed/33196008
http://dx.doi.org/10.31138/mjr.31.3.295

Ejemplares similares